Expanding our therapeutic options: Beta blockers for breast cancer?
@article{Ganz2011ExpandingOT,
title={Expanding our therapeutic options: Beta blockers for breast cancer?},
author={Patricia A. Ganz and Steve W. Cole},
journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
year={2011},
volume={29 19},
pages={
2612-6
}
}Figures from this paper
26 Citations
Drug Repurposing for Triple-Negative Breast Cancer
- Biology, ChemistryJournal of personalized medicine
- 2020
This review specially emphasizes the most relevant research, both at preclinical and clinical settings, aimed at repurposing pre-existing drugs to treat TNBC on the basis of molecular mechanisms and signaling pathways such as androgen receptor, adrenergic receptor, STAT3, nitric oxide synthase, or AXL.
Neurons generated from carcinoma stem cells support cancer progression
- BiologySignal Transduction and Targeted Therapy
- 2017
It is shown that a fraction of cancer stem cells (CSCs) derived from patients with gastric carcinoma and colorectal carcinoma are capable of producing neurons that are involved in tumor neurogenesis and tumor growth.
β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells
- Biology, ChemistryCancer biology & therapy
- 2015
It is shown that cholera toxin and βAR activation phosphorylate Rap1B and inhibit its prenylation and membrane localization, reducing cell-cell adhesion and promoting cell scattering, and that breast cancer cell migration is decreased by the FDA-approved β-blocker, propranolol.
β2-AR signaling controls trastuzumab resistance-dependent pathway
- Biology, ChemistryOncogene
- 2015
It is shown that the expression of β2-AR, which mediates most catecholamine-induced effects, negatively correlates with trastuzumab response in the patients with Her2-overexpressing breast cancer, implicating the possibility for combination therapy withtrastuzumsumab plus β-blocker in Her1-ovexpressing Breast cancer.
Sympathetic nervous system regulation of the tumour microenvironment
- Biology, MedicineNature Reviews Cancer
- 2015
In addition to identifying a molecular basis for physiologic stress effects on cancer, these findings have also identified new pharmacological strategies to inhibit cancer progression in vivo.
A Her2-let-7-β2-AR circuit affects prognosis in patients with Her2-positive breast cancer
- Biology, MedicineBMC Cancer
- 2015
The data suggest that β2-AR may be a new useful biomarker for predicting prognosis in Her2-positive breast cancer and may also be a promising selective therapeutic target for the aggressive subtype of breast cancer.
Long-Term Use of Antihypertensive Agents and Risk of Breast Cancer: A Population-Based Case–Control Study
- MedicineCardiology and Therapy
- 2015
Long-term use of CCBs or beta-1 selective beta-blockers are likely to be associated with the risk of breast cancer, according to the results of the analysis.
References
SHOWING 1-10 OF 50 REFERENCES
Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.
- Medicine, Biology
- 2010
This proof-of-principle study showed beta-blocker therapy significantly reduces distant metastases, cancer recurrence, and cancer-specific mortality in breast cancer patients suggesting a novel role for beta- blocker therapy.
The b 2-adrenergic receptor and Her 2 comprise a positive feedback loop in human breast cancer cells
- Biology, Chemistry
- 2010
The data indicate that Her2 overexpression and excessive phosphorylation of ERK cause epinephrine autocrine release from breast cancer cells, resulting in up-regulation of b2-AR expression, which supports a model where b 2-AR and Her2 comprise a positive feedback loop in human Breast cancer cells.
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.
- MedicineJournal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2011
BB intake was associated with improved RFS in all patients with breast cancer and in patients with TNBC, and additional studies evaluating the potential benefits of beta-adrenergic blockade on breast cancer recurrence are warranted.
Epinephrine Protects Cancer Cells from Apoptosis via Activation of cAMP-dependent Protein Kinase and BAD Phosphorylation*
- BiologyJournal of Biological Chemistry
- 2007
Evidence is provided that epinephrine reduces sensitivity of cancer cells to apoptosis through interaction with β2-adrenergic receptors, which could be one of the mechanisms by which stress promotes tumorigenesis and decreases the efficacy of anti-cancer therapies.
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
- MedicineJournal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2009
Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pCR rate than do diabetics not receiving meetformin, and additional studies to evaluate the potential of met formin as an antitumor agent are warranted.
C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study.
- MedicineJournal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2006
Baseline CRP levels seem to be a biomarker of chronic inflammation preceding lung cancer, even after subtracting a 5-year latent period, and both chronic inflammation and impaired defense mechanisms resulting in chronic inflammation might explain these results.
Tumor-host interactions: a far-reaching relationship.
- BiologyJournal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2010
This review addresses the recent advances in the understanding of the contributions of local and systemic environments to cancer progression, the ability of tumors to actively perturb the host environment, and current therapeutic approaches that are designed to disrupt tumor-host relationships.
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.
- MedicineJournal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2009
Circulating SAA and CRP may be important prognostic markers for long-term survival in breast cancer patients, independent of race, tumor stage, race, and body mass index.